Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNG001 for viral infection-associated COPD symptom worsening
2010-022110-29Phase 2Unknown
- Sponsor
- Synairgen
- Start
- Aug 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing SNG001 with Placebo (2 arms). Primary endpoint: Peak EXACT-PRO score between days 3 and 14. Status: unknown.
02
Drugs
interferon beta-1a
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-022110-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022110-29.